Affordable Access

deepdyve-link
Publisher Website

HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management.

Authors
  • Maxwell, Jessica H1
  • Grandis, Jennifer R2
  • Ferris, Robert L1, 3
  • 1 Department of Otolaryngology, MedStar Georgetown University Hospital, Washington DC 20007; email: [email protected]
  • 2 Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, California 94143; email: [email protected]
  • 3 Cancer Immunology Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232; email: [email protected]
Type
Published Article
Journal
Annual Review of Medicine
Publisher
Annual Reviews
Publication Date
2016
Volume
67
Pages
91–101
Identifiers
DOI: 10.1146/annurev-med-051914-021907
PMID: 26332002
Source
Medline
Keywords
License
Unknown

Abstract

Human papillomavirus (HPV) is a recently identified causative agent for a subset of head and neck cancers, primarily in the oropharynx, and is largely responsible for the rising worldwide incidence of oropharyngeal cancer (OPC). Patients with HPV-positive OPC have distinct risk factor profiles and generally have a better prognosis than patients with traditional, HPV-negative, head and neck cancer. Concurrent chemotherapy and radiation is a widely accepted primary treatment modality for many patients with HPV-positive OPC. However, recent advances in surgical modalities, including transoral laser and robotic surgery, have led to the reemergence of primary surgical treatment for HPV-positive patients. Clinical trials are under way to determine optimal treatment strategies for the growing subset of patients with HPV-positive OPC. Similarly, identifying those patients with HPV-positive cancer who are at risk for recurrence and poor survival is critical in order to tailor individual treatment regimens and avoid potential undertreatment.

Report this publication

Statistics

Seen <100 times